Johnson & Johnson drives peripheral artery disease awareness in new ‘Save Legs’ initiative
Spurred by new claims data, Johnson & Johnson’s Janssen is launching a “robust intervention” around peripheral artery disease (PAD). The new “Save Legs. Change Lives” effort aims to drive urgency and action around the often under-the-radar circulatory disease.
The findings J&J said are concerning — culled from insurance claims data — show that 61% of people in the US who undergo vascular procedures for PAD were unaware that they had the condition. And although PAD is a known leading cause of amputation in the US, among patients who undergo a leg amputation an alarming 70% die within three years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.